The supply of blood products to developing countries has been significantly raised by the World Federation of Hemophilia Humanitarian Aid Programme, it has been announced.
New figures show that 500 million international units of clotting factor treatment products are due to be donated over the next five years from two biotech companies.
Together with these products, the companies have promised 'substantial financial support' for the continuing operational needs of the programme.
Since its launch in 1996, the World Federation of Hemophilia Humanitarian Aid Programme 'has resulted in significant improvements in the lives of those living with bleeding disorders in developing countries throughout the world,' said Alain Weill, President of the World Federation of Hemophilia.
The Programme has so far channelled over 462 million international units of treatment products to over 100,000 patients in 90 countries.
Mr Weill continued: 'The Humanitarian Aid Programme has transformed, over the past two years, into one of the most effective global programs in addressing the significant treatment gaps that occur for those living without much needed care.'
Mark Skinner, USA President of the World Federation of Hemophilia, added: 'The Programme is an integral part of addressing the major gaps that exist for the majority of people in the world living with a bleeding disorder.
'The ongoing support of Bioverativ and Sobi to this program demonstrates strong leadership in providing certainty to those most in need. We continue to work with all our global partners to come together to further strengthen the success of the World Federation of Hemophilia Humanitarian Aid Programme.'
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.